VIR News and Press, Vir Biotechnology Inc. From 07/20/23

2023-07-20 08:46:16 ET Vir Biotechnology ( NASDAQ: VIR ) fell ~40% pre-market Thursday after the company said that its Phase 2 trial for VIR-2482, a monoclonal antibody targeted at the prevention of influenza A, did not meet its main goals. In terms of its primary endpoint, ...

SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA ( P rev E ntio N of I ll N es S D U e to Inf L uenza A ) trial evaluating VIR-2482 for the prevention of symptomatic influenza A il...

SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company’s st...

– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg) and higher rates of HBsAg loss compared to antivirals...

2023-06-13 06:37:41 ET Summary Vir Biotechnology presents a unique investment opportunity with a promising pipeline of viral therapeutics targeting hepatitis B, HIV, and influenza A, backed by strong financials and strategic collaborations. Vir's robust financial portfolio, effect...

2023-06-07 07:00:00 ET Summary High-yield dividend stocks are appealing, but they carry high amounts of risk. I demonstrate multiple examples. We present our new strategy to achieve high yields and 76 trades to snipe at market open. Written by Sam Kovacs Intr...

SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both hepatitis B virus (HBV) and hepatitis D virus (HDV) have been accepted for presentat...

SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44 th Annual Goldman Sachs Global Healthcare Conference on Monday, ...

2023-05-22 05:00:00 ET Summary Pharmaceuticals/biotechnology and healthcare providers still have good value scores. Healthcare equipment is the less attractive subsector. Fast facts on IHF, a healthcare providers ETF. 10 stocks cheaper than their peers in May. ...

SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via l...